Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches
Ischemia/Reperfusion Injury: Pathophysiology, Current Clinical Management, and Potential Preventive Approaches
复制标题
DOI：
10.1155/2020/8405370
复制
发表时间：
2020-01-29
影响因子：
4.6
通讯作者：
Peon, Alberto N.
中科院分区：
文献类型：
--
作者：
Daniel Sanchez-Hernandez, Cesar;Aide Torres-Alarcon, Lucero;Peon, Alberto N.
心肌缺血再灌注综合征是一个复杂的实体，其中许多炎症介质发挥不同的作用，既增强心肌梗死衍生的损伤，又愈合损伤。在这种情况下，建立一种有效的治疗方法来治疗这种疾病一直是难以捉摸的，也许是因为实验性治疗已经被认为只是阻断疾病的许多致病途径之一，或者因为它们阻碍了综合征的组织修复阶段。无论哪种方式，我们认为，对疾病的病理生理学和某些药物的作用机制的讨论可能会使这个话题变得更加清晰。
Myocardial ischemia reperfusion syndrome is a complex entity where many inflammatory mediators play different roles, both to enhance myocardial infarction-derived damage and to heal injury. In such a setting, the establishment of an effective therapy to treat this condition has been elusive, perhaps because the experimental treatments have been conceived to block just one of the many pathogenic pathways of the disease, or because they thwart the tissue-repairing phase of the syndrome. Either way, we think that a discussion about the pathophysiology of the disease and the mechanisms of action of some drugs may shed some clarity on the topic.